Literature DB >> 19730779

Outcome of fully awake craniotomy for lesions near the eloquent cortex: analysis of a prospective surgical series of 79 supratentorial primary brain tumors with long follow-up.

Luiz Claudio Modesto Pereira1, Karina M Oliveira, Gisele L L'Abbate, Ricardo Sugai, Joines A Ferreira, Luiz A da Motta.   

Abstract

BACKGROUND: Despite possible advantages, few surgical series report specifically on awake craniotomy for intrinsic brain tumors in eloquent brain areas.
OBJECTIVES: Primary: To evaluate the safety and efficacy of fully awake craniotomy (FAC) for the resection of primary supratentorial brain tumors (PSBT) near or in eloquent brain areas (EBA) in a developing country. Secondary: To evaluate the impact of previous surgical history and different treatment modalities on outcome. PATIENTS AND METHODS: From 1998 to 2007, 79 consecutive FACs for resection PSBT near or in EBA, performed by a single surgeon, were prospectively followed. Two groups were defined based on time period and surgical team: group A operated on from March 1998 to July 2004 without a multidisciplinary team and group B operated on from August 2004 to October 2007 in a multidisciplinary setting. For both time periods, two groups were defined: group I had no previous history of craniotomy, while group II had undergone a previous craniotomy for a PSBT. Forty-six patients were operated on in group A, 46 in group B, 49 in group I and 30 in group II. Psychological assessment and selection were obligatory. The preferred anesthetic procedure was an intravenous high-dose opioid infusion (Fentanil 50 microg, bolus infusion until a minimum dose of 10 microg/kg). Generous scalp and periosteous infiltrations were performed. Functional cortical mapping was performed in every case. Continuous somato-sensory evoked potentials (SSEPs) and phase reversal localization were available in 48 cases. Standard microsurgical techniques were performed and monitored by continuous clinical evaluation.
RESULTS: Clinical data showed differences in time since clinical onset (p < 0.001), slowness of thought (p = 0.02) and memory deficits (p < 0.001) between study periods and also time since recent seizure onset for groups I and II (p = 0.001). Mean tumor volume was 51.2 +/- 48.7 cm3 and was not different among the four groups. The mean extent of tumor reduction was 90.0 +/- 12.7% and was similar for the whole series. A trend toward a larger incidence of glioblastoma multiforme occurred in group B (p = 0.05) and I (p = 0.04). Recovery of previous motor deficits was observed in 75.0% of patients, while motor worsening in 8.9% of cases. Recovery of semantic language deficits, control of refractory seizures and motor worsening were statistically more frequent in group B (p = 0.01). Satisfaction with the procedure was reported by 89.9% of patients, which was similar for all groups. Clinical complications were minimal, and surgical mortality was 1.3%.
CONCLUSIONS: These data suggest that FAC is safe and effective for the resection of PSBT in EBA as the main technique, and in a multidisciplinary context is associated with greater clinical and physiological monitoring. The previous history of craniotomy for PSBT did not seem to influence the outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19730779     DOI: 10.1007/s00701-009-0363-9

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  17 in total

1.  [Anesthesiology: partner or competitor?].

Authors:  C M Körner; M A Weigand; E Martin
Journal:  Chirurg       Date:  2012-04       Impact factor: 0.955

2.  Operative treatment of subcortical metastatic tumours in the central region.

Authors:  J Walter; S A Kuhn; A Waschke; R Kalff; C Ewald
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

3.  Combination of Continuous Dexmedetomidine Infusion with Titrated Ultra-Low-Dose Propofol-Fentanyl for an Awake Craniotomy.

Authors:  Samaresh Das; Ali Al-Mashani; Neelam Suri; Neeraj Salhotra; Nilay Chatterjee
Journal:  Sultan Qaboos Univ Med J       Date:  2016-08-19

4.  [Application of diffusion tensor imaging combined with virtual reality three-dimensional reconstruction in the operation of gliomas involved eloquent regions].

Authors:  S H Chen; J Yang; H B Han; D H Cui; J J Sun; C C Ma; Q Y He; G Z Lin; Y F Han; C Wu; K M Ma; Y B Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-18

Review 5.  Resection of supratentorial gliomas: the need to merge microsurgical technical cornerstones with modern functional mapping concepts. An overview.

Authors:  Giannantonio Spena; Pier Paolo Panciani; Marco Maria Fontanella
Journal:  Neurosurg Rev       Date:  2014-10-21       Impact factor: 3.042

6.  Standardized reporting of adverse events and functional status from the first 5 years of awake surgery for gliomas: a population-based single-institution consecutive series.

Authors:  Margret Jensdottir; Stanislav Beniaminov; Asgeir S Jakola; Oscar Persson; Fritjof Norrelgen; Sofia Hylin; Alexander Fletcher-Sandersjöö; Jiri Bartek
Journal:  Acta Neurochir (Wien)       Date:  2022-04-14       Impact factor: 2.816

Review 7.  Awake craniotomy for supratentorial gliomas: why, when and how?

Authors:  George M Ibrahim; Mark Bernstein
Journal:  CNS Oncol       Date:  2012-09

Review 8.  Functional Mapping for Glioma Surgery, Part 2: Intraoperative Mapping Tools.

Authors:  Ramin A Morshed; Jacob S Young; Anthony T Lee; Shawn L Hervey-Jumper
Journal:  Neurosurg Clin N Am       Date:  2020-11-05       Impact factor: 2.509

9.  Focal Cortical Surface Cooling is a Novel and Safe Method for Intraoperative Functional Brain Mapping.

Authors:  Kenji Ibayashi; Araceli R Cardenas; Hiroyuki Oya; Hiroto Kawasaki; Christopher K Kovach; Matthew A Howard; Michael A Long; Jeremy D W Greenlee
Journal:  World Neurosurg       Date:  2020-12-08       Impact factor: 2.104

10.  Combined awake craniotomy with endoscopic port surgery for resection of a deep-seated temporal lobe glioma: a case report.

Authors:  Lance Bodily; Arlan H Mintz; Johnathan Engh
Journal:  Case Rep Med       Date:  2013-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.